Understand the source comparison
Hexarelin News 2026: Research Applications Comparison
Growth Hormone Pulsatility Studies GHS-R1a receptor agonism → pulsatile GH release from pituitary somatotrophs 80–150 mcg/kg subcutaneous, 2× daily Serum GH concentration (peak and AUC), IGF-1 levels, pituitary GH mRNA expression Requires frequent blood sampli
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Growth Hormone Pulsatility Studies
- GHS-R1a receptor agonism → pulsatile GH release from pituitary somatotrophs
- 80–150 mcg/kg subcutaneous, 2× daily
- Serum GH concentration (peak and AUC), IGF-1 levels, pituitary GH mRNA expression
- Requires frequent blood sampling (every 15–30 min) to capture pulsatile release; GH has ~20 min half-life
- Well-established application with reproducible protocols; expect GH elevation within 15–30 minutes post-injection
- Cardiac Remodeling and Cardioprotection
- CD36 receptor binding → Akt phosphorylation → anti-apoptotic signaling
- 80–120 mcg/kg subcutaneous, 2× daily for 8–12 weeks
- Left ventricular mass, ejection fraction, fibrosis markers (collagen I/III), cardiomyocyte apoptosis (TUNEL staining)
- Long-term dosing required; cardiac MRI or echocardiography for functional measures; histological endpoints essential
- Hexarelin news 2026 positions this as the most promising application; GH-independent pathway makes it mechanistically distinct
- Ischemia-Reperfusion Injury Models
- CD36-dependent mitochondrial protection → reduced infarct size
- 80 mcg/kg as single bolus pre-ischemia or at reperfusion
- Infarct size (TTC staining), serum troponin, myocardial contractility, mitochondrial ROS production
- Timing critical. Administer immediately before or at reperfusion; CD36 expression should be verified in tissue
- Strong preclinical evidence; effect size (40–60% infarct reduction) makes this a high-value research area
- Aging and Sarcopenia Studies
- Dual mechanism: GH/IGF-1 axis + direct muscle CD36 effects on fatty acid metabolism
- 100–150 mcg/kg subcutaneous, 2× daily for 12+ weeks
- Lean body mass (DEXA), grip strength, muscle fiber cross-sectional area, protein synthesis rates
- Requires aged animal cohorts; control for dietary protein and activity levels; IGF-1 often measured as mechanistic check
- Mixed outcomes in literature. Effect size smaller than selective GH secretagogues; CD36 role in muscle not fully characterized